Stock listing

NASDAQ:FBLG FibroBiologics, Inc. Stock

Home listing (NASDAQ) of FibroBiologics, Inc.

Follow FibroBiologics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:FBLG

$0.705 USD -0.135 (-16.1%)

Close on Nov 20, 2026

Past year -89.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.705 – $0.872 USDNov 20, 2026
Volume
49,626 sharesNov 20, 2026
Market cap
$6.34M USDAt the close on Nov 20, 2026 · price × 8.99M shares outstanding
52-week range
$0.620 – $9.598 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$249,592 USDMedian day 116,700 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
FibroBiologics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:FBLG · Home$0.705 USD-0.135 (-16.1%)49,626$0.872$0.872$0.705$0.840Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:FBLG · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.705-0.135-16.1%$0.872$0.872$0.70549,626
$0.840-0.061-6.7%$0.940$0.940$0.80086,304
$0.901-0.003-0.3%$0.930$0.960$0.89378,311
$0.903-0.024-2.6%$0.946$0.950$0.89097,460
$0.927-0.041-4.2%$1.020$1.020$0.92135,455
$0.968-0.028-2.8%$1.010$1.010$0.93334,182
$0.996+0.072+7.8%$0.940$1.040$0.92054,336
$0.924-0.034-3.5%$0.930$0.966$0.92459,674
$0.958-0.022-2.2%$0.912$0.966$0.91259,415
$0.980+0.023+2.4%$0.940$0.980$0.91141,010
$0.957-0.012-1.2%$1.000$1.000$0.91081,390
$0.969-0.021-2.2%$1.040$1.040$0.94159,736
$0.990+0.070+7.6%$0.935$0.990$0.90141,764
$0.920-0.010-1.1%$0.920$0.960$0.92042,364
$0.930+0.002+0.2%$0.920$0.970$0.90020,671
$0.928-0.039-4.0%$0.940$0.990$0.92317,857
$0.967+0.035+3.8%$0.929$0.993$0.91032,010
$0.932-0.008-0.9%$0.970$0.990$0.92926,590
$0.940-0.010-1.1%$0.930$0.950$0.890156,618
$0.950-0.070-6.9%$1.020$1.020$0.950111,922
$1.020+0.027+2.7%$0.970$1.240$0.970399,071
$0.993+0.073+7.9%$0.900$1.000$0.900127,507
$0.920-0.024-2.6%$0.930$0.971$0.88194,090
$0.944-0.027-2.8%$0.980$0.980$0.940170,331
$0.971-0.029-2.9%$1.020$1.040$0.95036,000
$1.000+0.050+5.3%$0.960$1.050$0.960156,200
$0.950-0.010-1.0%$1.000$1.020$0.925109,100
$0.960-0.040-4.0%$1.000$1.025$0.93380,600
$1.000-0.130-11.5%$1.120$1.135$0.989152,000
$1.130+0.020+1.8%$1.110$1.200$1.100182,300
$1.110-0.030-2.6%$1.120$1.140$1.05071,900
$1.140+0.010+0.9%$1.160$1.200$1.070233,800
$1.130-0.050-4.2%$1.200$1.230$1.120210,300
$1.180-0.060-4.8%$1.240$1.240$1.18094,100
$1.240+0.035+2.9%$1.200$1.240$1.100148,600
$1.205-0.095-7.3%$1.320$1.320$1.160140,100
$1.300-0.010-0.8%$1.350$1.400$1.280107,300
$1.310-0.050-3.7%$1.380$1.410$1.260191,800
$1.360-0.030-2.2%$1.440$1.480$1.340241,600
$1.390+0.030+2.2%$1.350$1.390$1.33055,400
$1.360+0.030+2.3%$1.350$1.470$1.330258,600
$1.330-0.010-0.7%$1.320$1.450$1.31087,300
$1.340-0.020-1.5%$1.350$1.410$1.33095,800
$1.360-0.070-4.9%$1.460$1.460$1.290116,700
$1.430-0.055-3.7%$1.540$1.540$1.400130,700
$1.485+0.055+3.8%$1.530$1.587$1.460105,100
$1.430-0.010-0.7%$1.440$1.490$1.386117,100
$1.440-0.110-7.1%$1.550$1.575$1.440177,100
$1.550-0.060-3.7%$1.600$1.690$1.521174,500
$1.610-0.120-6.9%$1.700$1.736$1.610107,300
$1.730-0.030-1.7%$1.730$1.796$1.67183,700
$1.760+0.050+2.9%$1.730$1.800$1.620135,900
$1.710-0.100-5.5%$1.800$1.816$1.619166,400
$1.810+0.050+2.8%$1.730$1.900$1.710210,456
$1.760-0.190-9.7%$1.800$1.901$1.700366,002
$1.950-0.160-7.6%$2.170$2.175$1.865639,026
$2.110+0.390+22.7%$1.730$2.200$1.7201,545,221
$1.720+0.280+19.4%$1.460$1.790$1.401508,098
$1.440-0.050-3.4%$1.500$1.540$1.410143,785
$1.490+0.080+5.7%$1.440$1.520$1.420217,830
$1.410+0.010+0.7%$1.390$1.470$1.330164,686
$1.400+0.050+3.7%$1.340$1.490$1.330191,303
$1.350-0.090-6.2%$1.420$1.500$1.310252,938
$1.440+0.150+11.6%$1.350$1.489$1.340570,614
$1.290+0.100+8.4%$1.220$1.370$1.200415,522

Splits

1 split · NASDAQ:FBLG · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
Ticker
NASDAQ:FBLG
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All FibroBiologics, Inc. news

FibroBiologics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
59 in the last 12 months · 121 in all · newest Nov 16, 2026 · oldest 2024
Decks
2 decks · latest September 2026

Where FibroBiologics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:FBLG · Home listing · This pageNASDAQUnited StatesUSD
BOATS:FBLGBOATSUnited StatesUSD
Frankfurt:SG00FrankfurtGermanyEUR
Lang & Schwarz:A426UVLang & SchwarzGermanyEUR
LS Exchange:A426UVLS ExchangeGermanyEUR

Valuation

Price/book 3.5× against a median of 1.0×: 8th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$5.17M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
3.5×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.34

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
FibroBiologics, Inc. · NASDAQ:FBLGUS$6.34MUS$5.17Mn/an/an/a3.5×n/a0.0×0.34
Aligos Therapeutics, Inc. · NASDAQ:ALGSUS$6.64M−US$12.55Mn/a−2.1×n/a0.6×n/a1.1×1.63
ZEO ScientifiX Inc. · OTC:ZEOXUS$6.51MUS$5.27Mn/a1.0×n/an/a−106.2%n/a0.54
GT Biopharma, Inc. · NASDAQ:GTBPUS$6.33M−US$3.60Mn/an/an/a0.8×n/a0.0×1.57
Kyntra Bio, Inc. · NASDAQ:KYNBUS$6.32M−US$33.97Mn/a−6.4×n/an/a−326.0%n/a1.58
Acurx Pharmaceuticals, Inc. · NASDAQ:ACXPUS$6.30M−US$3.35Mn/an/an/a0.9×n/a0.0×1.31
TrivarX Limited · ASX:TRIUS$6.11MUS$4.58Mn/an/an/a0.6×n/a0.0×n/a
Enveric Biosciences, Inc. · NASDAQ:ENVBUS$6.04MUS$429,455n/an/an/a1.1×n/a0.0×0.76
Medicofarma Biotech Spolka Akcyjna · NEWCONNECT:MDBUS$6.03MUS$6.03Mn/a314×n/a5.4×n/a0.0×n/a
Addex Therapeutics Ltd · SIX:ADXNUS$5.96MUS$5.13Mn/a68.2×n/a2.6×n/a0.0×n/a
Argenica Therapeutics Ltd · ASX:AGNUS$5.95MUS$1.74Mn/an/an/a1.5×n/a0.0×n/a
Median of the othersUS$6.20MUS$1.08M1.0×1.0×−216.1%0.0×1.44

Forecasts

1 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.

Price target
12.50 USD · Analysts' mean
EPS, year to Dec 2026
-3.00 · 1 analyst

Team and board

Officers

OfficerRole
Pete O’HeeronChairman/Founder/CEO
Jason D. DavisChief Financial Officer
Ruben GarciaGeneral Counsel
Hamid KhojaChief Scientific Officer

Board

DirectorRole
Pete O’HeeronChairman/Founder/CEO
Brain HealthDirector
Kathleen RubinsBoard of Directors
Leigh SteinbergBoard of Directors
Richard C. CilentoBoard of Directors
Robert E. HoffmanBoard of Directors
Victoria NiklasBoard of Directors

Events

QuarterResultsShare move
Q3 2026Nov 16, 2026 · After close−0.3%
Q2 2026Jul 31, 2026 · After close+12.9%
Q1 2026May 1, 2026+4.5%
Q4 2025Feb 24, 2026 · After close−1.6%
Q3 2025Oct 31, 2025 · After close+0.3%
Q2 2025Aug 14, 2025 · After close−2.5%
Q1 2025May 14, 2025 · After close+22.7%
Q4 2024Mar 31, 2025 · After close−4.4%
Q3 2024Nov 12, 2024 · After close−2.8%
Q2 2024Aug 7, 2024 · After close−39.4%
All 11 quarters
QuarterResultsShare move
Q1 2024May 29, 2024+2.8%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck19 slidesSeptember 2026
Investor Day (December 2023)Investor day33 slidesDecember 2023

Open Decks

Financings

RaiseDate
Private placement of shares of common stock and accompanying warrants
Closed: US$500,000 raised · US$1.675 a share · Warrants at US$1.55 for 60 months
Buyers: Hamid Khoja, Ph.D. (298,508 shares of common stock and accompanying warrants to purchase up to 298,508 shares)
Insiders: The entire placement was purchased by Chief Scientific Officer Hamid Khoja, Ph.D.
Use of proceeds: General corporate purposes and working capital
Sep 17, 2026
Private placement of shares of common stock (or pre-funded warrants) with series A and short-term series B warrants
Closed: US$3M raised · US$0.735 a share · Warrants at US$0.735 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and general corporate purposes
Jun 29, 2026
Registered direct offering of registered direct offering
Closed: US$2.5M raised
Apr 30, 2026
Registered direct offering of common stock, with concurrent private placement of unregistered warrants
Closed: US$1.7M raised · US$0.33 a share · Warrants at US$0.33 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and general corporate purposes
Dec 16, 2025
Registered direct offering of common stock, with concurrent private placement of unregistered warrants
Closed: US$1.5M raised · US$0.335 a share · Warrants at US$0.335 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and general corporate purposes
Nov 25, 2025
Registered direct offering of common stock and pre-funded warrants, with concurrent private placement of unregistered warrants
Closed: US$4M raised · US$0.3303 a share · Warrants at US$0.3303 for 60 months
Buyers: existing shareholder (3,540,000 shares of common stock and pre-funded warrants to purchase 8,570,203 shares, paid with gold coins)
Use of proceeds: General corporate purposes, including the satisfaction of debt
Nov 20, 2025
Convertible promissory notes (advances under SEPA)
Tranche closed: US$5M in the latest tranche · D. Boral Capital LLC
Dealers: D. Boral Capital LLC (lead)
Buyers: YA II PN LTD. (Yorkville) (Up to $25 million of common stock over two years; first $15 million advanced via convertible promissory notes, $5 million funded); YA II PN, LTD. (Yorkville) (third $5 million tranche of convertible promissory notes under the SEPA)
Use of proceeds: General corporate purposes, including R&D programs and the upcoming Phase 1/2 diabetic foot ulcer clinical trial
Jun 16, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2026FY2025FY2025FY2024FY2024FY2023FY2023FY2022FY2022FY2021
Revenue00000
Cost of revenue832.0K573.0K437.0K94.0K
Gross profit-832.0K-573.0K-437.0K-94.0K
Research and development7.41M7.41M4.50M4.50M2.37M2.37M1.15M1.15M521.0K669.0K
Selling, general and administrative9.24M9.23M6.52M3.32M1.06M500.0K
Operating income-16.6M-16.6M-13.7M-13.7M-8.89M-8.89M-4.47M-4.47M-1.58M-1.17M
Depreciation and amortization832.0K244.0K573.0K157.0K437.0K47.0K94.0K01.17M
EBITDA-15.8M-16.4M-13.2M-13.6M-8.45M-8.84M-4.37M-1.58M0
Interest expense204.0K204.0K20.0K20.0K147.0K147.0K654.0K654.0K4.00K
Income before tax-18.6M-11.2M-16.5M-5.12M-1.58M-1.17M
Income tax0000
Net income-18.6M-18.6M-11.2M-11.2M-16.5M-16.5M-5.12M-5.12M-1.58M-1.17M
Earnings per share, basic-8.35-0.42-6.79-0.34-10.15-0.68-3.15-0.18-0.97-0.72
Earnings per share, diluted-0.42-0.34-0.68-0.18

Balance sheet

LineFY2026FY2025FY2025FY2024FY2024FY2023FY2023FY2022FY2022FY2021
Cash and equivalents4.89M4.89M14.0M14.0M9.16M9.16M2.27M2.27M407.0K
Receivables300.0K300.0K
Current assets6.35M6.35M14.2M14.2M9.21M9.21M2.63M2.63M468.0K
Property, plant and equipment842.0K824.0K797.0K
Total assets9.62M9.62M16.4M16.4M11.8M11.8M4.82M4.82M468.0K
Accounts payable945.0K2.70M1.44M758.0K233.0K
Current liabilities1.76M1.76M12.7M12.7M9.18M9.18M7.07M7.07M1.76M
Total debt2.41M10.6M1.75M7.52M1.30M
Total liabilities3.46M3.46M13.7M13.7M10.6M10.6M8.82M8.82M1.76M
Shareholders' equity6.16M6.16M2.73M2.73M1.25M1.25M-4.00M-4.00M-1.29M
Shares outstanding2.23M8.99M1.64M8.99M1.62M67.6M1.62M37.7M1.62M1.62M

Cash flow

LineFY2026FY2025FY2025FY2024FY2024FY2023FY2023FY2022FY2022FY2021
Cash from operations-16.4M-16.4M-11.9M-11.9M-6.40M-6.40M-4.07M-4.07M-1.41M-1.17M
Capital spending-262.0K-262.0K-184.0K-184.0K-495.0K-495.0K000
Free cash flow-16.7M-16.7M-12.1M-12.1M-6.90M-6.90M-4.07M-1.41M-1.17M
Cash from investing-262.0K-262.0K-184.0K-184.0K-495.0K-495.0K
Cash from financing7.57M7.57M16.9M16.9M13.8M13.8M5.92M5.92M1.82M1.17M
Change in cash-9.09M-9.09M4.82M4.82M6.90M6.90M1.86M1.86M407.0K

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveOct 20, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveOct 20, 2026Other filingsSEC
POS AM · Amendment to an effective registrationOct 13, 2026Offer documentSEC
POS AM · Amendment to an effective registrationOct 13, 2026Offer documentSEC
DOct 13, 2026Other filingsSEC
8-K · Current reportOct 8, 2026Material contractSEC
8-K · Current reportSep 18, 2026Meeting outcomeSEC
SCHEDULE 13D · Big-stake noticeSep 17, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipSep 15, 2026Insider tradeSEC
DSep 15, 2026Other filingsSEC
8-K · Current reportSep 15, 2026Material contractSEC
DEFA14A · Additional proxy materialSep 9, 2026Meeting noticeSEC
3 · Initial statement of ownershipSep 1, 2026Insider tradeSEC
8-K · Current reportAug 24, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportJul 31, 2026Quarterly reportSEC
DEF 14A · Proxy statementJul 31, 2026Meeting noticeSEC
8-K · Current reportJul 24, 2026Current reportSEC
PRE 14A · Preliminary proxy statementJul 17, 2026Meeting noticeSEC
EFFECT · Notice that a registration is effectiveJul 17, 2026Other filingsSEC
424B3 · ProspectusJul 16, 2026Offer documentSEC
3 · Initial statement of ownershipJul 16, 2026Insider tradeSEC
S-3 · Registration statementJul 9, 2026Offer documentSEC
8-K · Current reportJul 9, 2026Management or board changeSEC
DJun 29, 2026Other filingsSEC
8-K · Current reportJun 29, 2026Material contractSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
8-K · Current reportJun 23, 2026Management or board changeSEC
8-K · Current reportMay 6, 2026Material contractSEC
424B5 · ProspectusMay 5, 2026Offer documentSEC
8-K · Current reportMay 5, 2026Management or board changeSEC
ARS · Annual report to shareholdersMay 5, 2026Annual reportSEC
DEFA14A · Additional proxy materialMay 5, 2026Meeting noticeSEC
DEF 14A · Proxy statementMay 5, 2026Meeting noticeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
424B5 · ProspectusMay 1, 2026Offer documentSEC
8-K · Current reportMay 1, 2026Material contractSEC
10-Q · Quarterly reportApr 30, 2026Quarterly reportSEC
PRE 14A · Preliminary proxy statementApr 22, 2026Meeting noticeSEC
8-K · Current reportApr 20, 2026Current reportSEC
8-K · Current reportApr 17, 2026Current reportSEC
8-K/A · Current report, amendedApr 9, 2026Material contractSEC
SCHEDULE 13G · Big-stake noticeApr 9, 2026Big-stake noticeSEC
8-K · Current reportApr 9, 2026Material contractSEC
8-K · Current reportApr 3, 2026Current reportSEC
8-K · Current reportApr 2, 2026Material contractSEC
424B4 · ProspectusApr 1, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 1, 2026Other filingsSEC
CORRESP · Letter to the SECMar 27, 2026Other filingsSEC
CORRESP · Letter to the SECMar 27, 2026Other filingsSEC
S-1 · Registration statementMar 27, 2026Offer documentSEC
UPLOAD · Letter from the SECMar 24, 2026Other filingsSEC
DRS · Draft registration statementMar 20, 2026Offer documentSEC
10-K/A · Annual report, amendedMar 13, 2026Annual reportSEC
8-K · Current reportMar 6, 2026Management or board changeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
10-K · Annual reportFeb 24, 2026Annual reportSEC
8-K · Current reportFeb 23, 2026Meeting outcomeSEC
8-K · Current reportFeb 6, 2026Current reportSEC
8-K · Current reportJan 2, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveDec 31, 2025Other filingsSEC
424B3 · ProspectusDec 30, 2025Offer documentSEC
CORRESP · Letter to the SECDec 29, 2025Other filingsSEC
UPLOAD · Letter from the SECDec 29, 2025Other filingsSEC
DEFA14A · Additional proxy materialDec 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementDec 29, 2025Meeting noticeSEC
S-1 · Registration statementDec 23, 2025Offer documentSEC
PRE 14A · Preliminary proxy statementDec 18, 2025Meeting noticeSEC
DEF 14A · Proxy statementDec 18, 2025Meeting noticeSEC
DDec 16, 2025Other filingsSEC
8-K · Current reportDec 15, 2025Material contractSEC
424B5 · ProspectusDec 15, 2025Offer documentSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
DDec 3, 2025Other filingsSEC
DDec 3, 2025Other filingsSEC
8-K · Current reportNov 25, 2025Material contractSEC
424B5 · ProspectusNov 25, 2025Offer documentSEC
424B5 · ProspectusNov 19, 2025Offer documentSEC
8-K · Current reportNov 19, 2025Material contractSEC
10-Q · Quarterly reportOct 31, 2025Quarterly reportSEC
8-K · Current reportAug 8, 2025Current reportSEC
10-Q · Quarterly reportJul 31, 2025Quarterly reportSEC
8-K/A · Current report, amendedJul 18, 2025FinancingSEC
8-K · Current reportJul 18, 2025FinancingSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 17, 2025Big-stake noticeSEC
8-K · Current reportJul 3, 2025Current reportSEC
8-K · Current reportJun 16, 2025Material contractSEC
8-K · Current reportJun 13, 2025Meeting outcomeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 10, 2025Insider tradeSEC
8-K · Current reportJun 9, 2025Management or board changeSEC
SCHEDULE 13G · Big-stake noticeJun 6, 2025Big-stake noticeSEC
4 · Change in ownershipMay 27, 2025Insider tradeSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 5, 2025Management or board changeSEC
ARS · Annual report to shareholdersApr 23, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 23, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 11, 2025Meeting noticeSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
4 · Change in ownershipMar 28, 2025Insider tradeSEC
4 · Change in ownershipMar 28, 2025Insider tradeSEC
4 · Change in ownershipMar 28, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 12, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveFeb 11, 2025Other filingsSEC
8-K · Current reportFeb 7, 2025FinancingSEC
CORRESP · Letter to the SECFeb 6, 2025Other filingsSEC
UPLOAD · Letter from the SECFeb 6, 2025Other filingsSEC
S-3 · Registration statementFeb 3, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 30, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 29, 2025Big-stake noticeSEC
8-K · Current reportJan 24, 2025Management or board changeSEC
EFFECT · Notice that a registration is effectiveJan 22, 2025Other filingsSEC
POS AM · Amendment to an effective registrationJan 17, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 15, 2025Other filingsSEC
424B4 · ProspectusJan 14, 2025Offer documentSEC
S-1/A · Registration statement, amendedJan 10, 2025Offer documentSEC
CORRESP · Letter to the SECJan 10, 2025Other filingsSEC
UPLOAD · Letter from the SECJan 6, 2025Other filingsSEC
8-K · Current reportDec 31, 2024Material contractSEC
4 · Change in ownershipDec 30, 2024Insider tradeSEC
4 · Change in ownershipDec 30, 2024Insider tradeSEC
4 · Change in ownershipDec 30, 2024Insider tradeSEC
S-1 · Registration statementDec 30, 2024Offer documentSEC
8-K · Current reportDec 23, 2024Material contractSEC
8-K · Current reportDec 20, 2024Material contractSEC
4 · Change in ownershipDec 9, 2024Insider tradeSEC
4 · Change in ownershipDec 5, 2024Insider tradeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportOct 29, 2024Management or board changeSEC
8-K · Current reportSep 24, 2024Material contractSEC
8-K · Current reportAug 28, 2024Meeting outcomeSEC
4 · Change in ownershipAug 27, 2024Insider tradeSEC
4 · Change in ownershipAug 27, 2024Insider tradeSEC
4 · Change in ownershipAug 27, 2024Insider tradeSEC
4 · Change in ownershipAug 27, 2024Insider tradeSEC
4 · Change in ownershipAug 27, 2024Insider tradeSEC
8-K · Current reportAug 27, 2024FinancingSEC
EFFECT · Notice that a registration is effectiveAug 15, 2024Other filingsSEC
POS AM · Amendment to an effective registrationAug 13, 2024Offer documentSEC
3/A · Initial statement of ownership, amendedAug 13, 2024Insider tradeSEC
3/A · Initial statement of ownership, amendedAug 13, 2024Insider tradeSEC
3/A · Initial statement of ownership, amendedAug 13, 2024Insider tradeSEC
3/A · Initial statement of ownership, amendedAug 13, 2024Insider tradeSEC
3/A · Initial statement of ownership, amendedAug 13, 2024Insider tradeSEC
3/A · Initial statement of ownership, amendedAug 13, 2024Insider tradeSEC
4 · Change in ownershipAug 12, 2024Insider tradeSEC
4 · Change in ownershipAug 12, 2024Insider tradeSEC
3/A · Initial statement of ownership, amendedAug 12, 2024Insider tradeSEC
3/A · Initial statement of ownership, amendedAug 12, 2024Insider tradeSEC
10-Q · Quarterly reportAug 7, 2024Quarterly reportSEC
ARS · Annual report to shareholdersJul 8, 2024Annual reportSEC
DEFA14A · Additional proxy materialJul 8, 2024Meeting noticeSEC
DEF 14A · Proxy statementJul 8, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementJun 27, 2024Meeting noticeSEC
8-K · Current reportJun 27, 2024Current reportSEC
424B4 · ProspectusJun 26, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 26, 2024Other filingsSEC
CORRESP · Letter to the SECJun 21, 2024Other filingsSEC
CORRESP · Letter to the SECJun 21, 2024Other filingsSEC
CORRESP · Letter to the SECJun 18, 2024Other filingsSEC
S-1 · Registration statementJun 18, 2024Offer documentSEC
UPLOAD · Letter from the SECJun 17, 2024Other filingsSEC
DRS · Draft registration statementJun 10, 2024Offer documentSEC
RW · Request to withdraw a registrationJun 6, 2024Other filingsSEC
S-1/A · Registration statement, amendedJun 4, 2024Offer documentSEC
S-1/A · Registration statement, amendedMay 15, 2024Offer documentSEC
S-8 · Registration statement for employee plansMay 15, 2024Offer documentSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportApr 26, 2024Current reportSEC
S-1 · Registration statementApr 25, 2024Offer documentSEC
DRS · Draft registration statementApr 12, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveMar 29, 2024Other filingsSEC
424B4 · ProspectusMar 28, 2024Offer documentSEC
CORRESP · Letter to the SECMar 27, 2024Other filingsSEC
S-1/A · Registration statement, amendedMar 26, 2024Offer documentSEC
CORRESP · Letter to the SECMar 26, 2024Other filingsSEC
UPLOAD · Letter from the SECMar 25, 2024Other filingsSEC
S-1/A · Registration statement, amendedMar 15, 2024Offer documentSEC
CORRESP · Letter to the SECMar 15, 2024Other filingsSEC
4 · Change in ownershipMar 8, 2024Insider tradeSEC
3 · Initial statement of ownershipMar 6, 2024Insider tradeSEC
10-K · Annual reportFeb 29, 2024Annual reportSEC
UPLOAD · Letter from the SECFeb 26, 2024Other filingsSEC

This page holds 200 of 244 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from FibroBiologics, Inc.’s releases · as of Nov 16, 2026

Common shares
8,989,475
Fully diluted
8,989,475

Fully diluted

LineSharesAs of
Common shares8,989,475Nov 16, 2026

Warrants and options

Lot
Warrants · US$1.55 · expire about Sep 2031
Warrants · US$0.74 · expire about Jun 2031
Warrants · US$0.33 · expire about Dec 2030
Warrants · US$0.34 · expire about Nov 2030
Warrants · US$0.33 · expire about Nov 2030

Share count over time

CountShares
Nov 16, 20268,989,475

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Armistice Capital, LLC656K7.3%US$853KSep 30, 2026
Cascade Financial Partners, LLC108K1.2%US$140KSep 30, 2026
Vanguard102K1.1%US$133KSep 30, 2026
Geode Capital30,1690.34%US$39,230Sep 30, 2026
IFP Advisors, Inc27,0000.30%US$35,100Sep 30, 2026
BlackRock18,2380.20%US$23,709Sep 30, 2026
Virtu Financial LLC12,1630.14%US$16,000Sep 30, 2026
Tower Research Capital LLC (TRC)3,1100.03%US$4,043Sep 30, 2026
Jones Financial Companies Lllp2,5000.03%US$3,475Sep 30, 2026
Osaic Holdings, Inc.2,3000.03%US$2,992Sep 30, 2026
All 18 holders
HolderSharesOf the companyValueAs of
RBC1,3800.02%US$2,000Sep 30, 2026
UBS1,0720.01%US$1,394Sep 30, 2026
Grove Bank & Trust100<0.01%US$130Sep 30, 2026
BNP Paribas64<0.01%US$83Sep 30, 2026
BFC Planning, Inc.50<0.01%US$65Sep 30, 2026
Barclays29<0.01%US$38Sep 30, 2026
Allworth Financial LP13<0.01%US$17Sep 30, 2026
Citigroup Inc1<0.01%US$1Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Extended Market Index Fund27,7690.31%US$26,317Jun 30, 2026
Fidelity Extended Market Index Fund19,5440.22%US$22,671May 31, 2026
Fidelity Series Total Market Index Fund2,5710.03%US$2,982May 31, 2026
Fidelity Total Market Index Fund2,2660.03%US$2,629May 31, 2026
Fidelity Nasdaq Composite Index Fund1,0990.01%US$1,275May 31, 2026

Big stakes

StakeStakeSharesDateFiling
Armistice Capital, LLC9.99%666KSep 30, 2026Schedule 13G
Hamid Khoja7.50%630KSep 15, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Robert E. Hoffman
Other companies: CytoDyn Inc. (Chief Financial Officer · Since at least May 15, 2025); Esperion Therapeutics, Inc. (Director · Since at least Apr 1, 2025); TuHURA Biosciences, Inc. (Director · Since at least Apr 11, 2018); Aravive Inc (Director · Oct 12, 2018 – Sep 12, 2019 · Past); Heron Therapeutics, Inc. (CFO & SVP, Finance · Apr 24, 2017 – Dec 19, 2019 · Past); Kura Oncology, Inc. (Director · May 12, 2016 – Jun 22, 2021 · Past); CombiMatrix Corp (Director · May 10, 2016 – Nov 14, 2017 · Past); MabVax Therapeutics Holdings Inc (Director · Aug 26, 2015 – May 19, 2017 · Past)
Director · Since at least Jan 24, 2024
Jason D. Davis
Other companies: Virax Biolabs Group Limited (Chief Financial Officer · Since at least Mar 18, 2026); Particle Drilling Technologies Inc (Interim Chief Financial Office · Jan 5, 2009 – Apr 17, 2009 · Past)
Chief Financial Officer · Since at least Jun 9, 2025
Matthew Link
Other companies: Sight Sciences, Inc. (Chief Commercial Officer · Since at least Sep 11, 2023)
Director · Since at least Jan 24, 2024
Pete O'Heeron
Other companies: Liberty Star Uranium & Metals Corp. (COB, Secretary, Treasurer, Director · Since at least Jul 31, 2019)
CHIEF EXECUTIVE OFFICER, Director · Since at least Jan 24, 2024
Stacy Ann Coen
Other companies: ImmunoGen Inc (SVP & CHIEF BUSINESS OFFICER · May 20, 2022 – Feb 12, 2024 · Past)
Director · Since at least Jan 24, 2024
Brain HealthDirector · Since at least Aug 24, 2026
Hamid KhojaChief Scientific Officer · Since at least Jan 24, 2024
Kathleen RubinsBoard of Directors · Since at least Jul 8, 2026
Leigh SteinbergBoard of Directors · Since at least Aug 24, 2026
Mark C AndersenChief Financial Officer · Jan 24, 2024 – Jan 24, 2024 · Past
All 14 people
PersonSeat
Pete O’HeeronChairman/Founder/CEO · Since at least Oct 14, 2026
Richard C. CilentoBoard of Directors · Since at least Nov 5, 2026
Ruben GarciaGeneral Counsel · Since at least Mar 1, 2024
Victoria NiklasDirector · Since at least Jan 24, 2024

Open People

Log in to ask 6ix AI your own questions about FibroBiologics, Inc.